Eli Lilly's $23 Billion Quarter: Can Foundayo Extend the Obesity Boom?
Eli Lilly stock analysis: Q2 2026 sales, Mounjaro, Zepbound, Foundayo, obesity-drug pricing, retatrutide and the investment risks ahead.
EXPLORE A LITTLE FURTHER
Mag8 research
1 stories from the Compound journal.